Roivant Sciences Ltd.
ROIV
$28.58
-$0.95-3.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.52M | 2.00M | 1.57M | 2.17M | 7.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.52M | 2.00M | 1.57M | 2.17M | 7.57M |
| Cost of Revenue | 199.27M | 166.08M | 164.18M | 152.57M | 145.04M |
| Gross Profit | -196.75M | -164.08M | -162.61M | -150.40M | -137.47M |
| SG&A Expenses | 173.07M | 175.05M | 129.53M | 128.22M | 227.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 372.33M | 341.13M | 293.70M | 280.79M | 372.74M |
| Operating Income | -369.81M | -339.14M | -292.13M | -278.62M | -365.17M |
| Income Before Tax | 454.10M | -290.37M | -159.04M | -269.26M | -203.05M |
| Income Tax Expenses | 98.35M | 23.33M | 7.00M | 4.65M | 49.32M |
| Earnings from Continuing Operations | 355.74M | -313.70M | -166.04M | -273.91M | -252.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -52.75M | 47.81M | 52.52M | 50.56M | 45.90M |
| Net Income | 302.99M | -265.89M | -113.52M | -223.36M | -206.48M |
| EBIT | -369.81M | -339.14M | -292.13M | -278.62M | -365.17M |
| EBITDA | -369.17M | -338.44M | -291.21M | -277.52M | -357.00M |
| EPS Basic | 0.43 | -0.38 | -0.17 | -0.33 | -0.29 |
| Normalized Basic EPS | -0.36 | -0.21 | -0.17 | -0.15 | -0.20 |
| EPS Diluted | 0.28 | -0.38 | -0.17 | -0.33 | -0.29 |
| Normalized Diluted EPS | -0.31 | -0.21 | -0.17 | -0.15 | -0.20 |
| Average Basic Shares Outstanding | 702.13M | 696.86M | 680.95M | 680.29M | 707.30M |
| Average Diluted Shares Outstanding | 812.29M | 696.86M | 680.95M | 680.29M | 707.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |